DelveInsight's,“ Advanced Melanoma Pipeline Insight 2025 ” report provides comprehensive insights about 55+ companies and 60+ pipel ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

Governor Revives ‘Asset Test’ For Medi-Cal Applicants: Gov. Gavin Newsom has proposed tackling the rising costs of Medi-Cal ...

It might sound basic, but data shows that focusing on healthy food and structured exercise might help patients with cancer live longer or respond to therapy. Other cancer news reports on immunotherapy ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

See related article at Key points Targeted therapy and immunotherapies are now treatment mainstays for an increasing number of cancers, often markedly improving patient survival and quality of life.

ASTANA – The National Research Oncology Center and the AstraZeneca biopharmaceutical company signed an agreement on May 30 to ...

Treating women with hormone receptor–positive, HER2-negative breast cancer using AstraZeneca’s (NASDAQ: AZN) experimental ...